{"id":459335,"date":"2021-03-17T03:03:25","date_gmt":"2021-03-17T07:03:25","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=459335"},"modified":"2021-03-17T03:03:25","modified_gmt":"2021-03-17T07:03:25","slug":"saniona-publishes-its-year-end-report-for-2020","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/saniona-publishes-its-year-end-report-for-2020\/","title":{"rendered":"Saniona publishes its year-end report for 2020"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">\n        <strong>PRESS RELEASE<\/strong>\n      <\/p>\n<p>\n        <strong>Financial highlights<\/strong><br \/>\n        \n      <\/p>\n<p align=\"justify\">\n        <strong>Jan &#8211; Dec 2020 (Jan &#8211; Dec 2019 restated)<\/strong><br \/>\n        <br \/>Revenue was SEK 8.2 M (7.2 M)<br \/>Operating loss was SEK -159.4 (-93.6 M)<br \/>Net loss was SEK -73.4 M (-68.8 M)<br \/>Earnings per share were SEK -1.79 (-2.67)<br \/>Diluted earnings per share were SEK -1.75 (-2.67)<\/p>\n<p align=\"justify\">\n        <strong>Q4 2020 (Q4 2019 restated)<\/strong><br \/>\n        <br \/>Revenue was SEK 1.6 M (0.0 M)<br \/>Operating loss was SEK -68.8 M (-28.2 M)<br \/>Net loss was SEK -45.6 M (-6.8 M)<br \/>Earnings per share were SEK -0.73 (-0.24)<br \/>Diluted earnings per share were SEK -0.73 (-0.24)<\/p>\n<p>\n        <b>Business highlights in Q4 2020<\/b><br \/>\n        \n      <\/p>\n<ul>\n<li>Saniona achieved <strong>positive top-line Phase 2 results<\/strong> from the open-label extension study of Tesomet in patients with HO. Patients treated with Tesomet for nearly one year (24 weeks in a double-blind trial followed by a 24-week open label extension) demonstrated statistically significant and clinically meaningful reductions in body weight and waist circumference, as well as improvements in glycemic control. Tesomet was well tolerated, and no clinically meaningful differences in heart rate or blood pressure were observed over the course of the 48-week trial.<\/li>\n<li>Saniona received written <strong>feedback from\u00a0the U.S. Food and Drug Administration (FDA)<\/strong> regarding pre-Investigational New Drug (IND) submissions for Tesomet in Prader-Willi syndrome (PWS) and HO. In both indications, the FDA recommended that the clinical development program include a supportive Phase 2b study followed by a Phase 3 study. Saniona anticipates initiating both Phase 2b studies in the first half of 2021.<\/li>\n<li>Saniona <strong>refined its pipeline<\/strong>, regaining exclusive, global rights to its GABAa5 negative allosteric modulator program from Boehringer Ingelheim, which terminated this collaboration for strategic reasons.\u00a0This does not impact the 2020 collaboration between Saniona and Boehringer Ingelheim, which remains ongoing. Separately,\u00a0Saniona and the Treatment Research Center (TRC) at the University of Pennsylvania jointly discontinued their collaboration to develop NS2359 for cocaine addiction. Saniona will evaluate the applicability of both programs in rare diseases.<\/li>\n<li>Saniona further <strong>strengthened its executive team<\/strong> with the addition of Denelle Waynick as Chief Legal Officer and Kyle Haraldsen as Chief Technical Operations Officer.<\/li>\n<\/ul>\n<p align=\"justify\">\n        <b>Significant events after the reporting period<\/b>\n      <\/p>\n<ul>\n<li>Saniona received an upfront payment of approximately <strong>USD 2.9 million (SEK 24.2 million) <\/strong>relating to Novartis\u2019s acquisition of Cadent Therapeutics, in which Saniona holds an ownership stake of approximately 3%. The acquisition may result in additional contingent consideration upon the achievement of future milestones.<\/li>\n<li>The U.S. FDA granted <strong>orphan drug designation<\/strong> to Tesomet for the treatment of PWS.\u00a0This designation qualifies Saniona for certain development benefits, including tax credits, elimination of certain FDA license application fees, and seven years of market exclusivity in the U.S. following approval.<\/li>\n<li>The U.S. FDA provided further clarity on a <strong>regulatory path for Tesomet in the treatment of HO<\/strong>. The FDA indicated overall agreement with Saniona\u2019s Risk Evaluation and Mitigation Strategy (REMS) proposal and cardiovascular monitoring proposal. Based on this feedback, Saniona is proceeding with plans to initiate a Phase 2b study in HO in the first half of this year.<\/li>\n<\/ul>\n<p>\n        <strong>Comments from the CEO\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/strong><br \/>\n        <br \/>&#8220;Throughout 2020, Saniona continued to execute on our strategy of discovering, developing and delivering innovative rare disease treatments: we generated positive data with Tesomet in both the double-blind and open-label extension periods of our Phase 2 study for hypothalamic obesity, we established our executive team and infrastructure in the U.S., and we attracted some of the most respected institutional investors in healthcare with the ability to support Saniona\u2019s long-term growth prospects,\u201d said Rami Levin, President &amp; Chief Executive Officer of Saniona. \u201cWe are currently in the strongest cash position of Saniona\u2019s history, which will allow us to conduct three clinical trials simultaneously: two Phase 2b trials for Tesomet in hypothalamic obesity and Prader-Willi syndrome and a Phase 1 trial of SAN711 for rare neuropathic disorders. We are well-positioned to continue with our transformation in 2021 as we advance our pipeline and position Saniona to access the U.S. patients, physicians and financial market which will be critical to realize our potential.\u201d<\/p>\n<p>As part of its evaluation of a potential U.S. listing, Saniona completed a company-initiated restatement of prior period financial statements and a subsequent audit of these financial statements under U.S. Public Company Accounting Oversight Board (PCAOB) audit standards. The restatements are included in the year-end report. The restatements relate to accounting adjustments and do not impact Saniona\u2019s cash position, forecast, operating plan or the conduct of our clinical trials. <\/p>\n<p>Read the full report attached below.<\/p>\n<p align=\"justify\">\n        <strong>For more information, please contact <\/strong><br \/>\n        <br \/>Trista Morrison, Chief Communications Officer, Saniona. Office: + 1 (781) 810-9227. Email: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-hpFM3lryEhdz6eRQsx7SVRksBam7RmLHD8kK8GKd_etMauEgH3xs1yFMsaHr534IfYAgUpU7UsZQBU0RxWTkeByaRO5Js2iZPQcsEV3YtxTwqnpy97pDCNkGfRXH_zO\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">trista.morrison@saniona.com<\/a><\/p>\n<p>\n        <em>This information is such information as Saniona AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:00 CET on March 17, 2021.<\/em>\n      <\/p>\n<p align=\"justify\">\n        <strong>About Saniona<\/strong><br \/>\n        <br \/>Saniona is\u00a0a\u00a0biopharmaceutical company focused on discovering, developing, and delivering innovative treatments for rare disease patients around the world. The company\u2019s lead product candidate, Tesomet, is in mid-stage clinical trials for hypothalamic obesity\u00a0and\u00a0Prader-Willi syndrome, severe rare disorders\u00a0characterized by uncontrollable hunger and\u00a0intractable\u00a0weight gain.\u00a0Saniona\u2019s\u00a0robust drug discovery engine\u00a0has\u00a0generated\u00a0a library now consisting of\u00a0more than 20,000 proprietary\u00a0modulators of ion channels, a\u00a0significantly untapped\u00a0drug class\u00a0that is\u00a0scientifically\u00a0validated.\u00a0Lead candidate SAN711 is entering Phase 1 for rare neuropathic disorders, with SAN903 for rare inflammatory and fibrotic disorders advancing through preclinical studies. Led by an experienced\u00a0scientific and operational\u00a0team,\u00a0Saniona\u00a0has an established research organization in Copenhagen, Denmark\u00a0and\u00a0is building its\u00a0corporate\u00a0office\u00a0in\u00a0the\u00a0Boston,\u00a0Massachusetts\u00a0area, U.S.\u00a0The company\u2019s shares are listed on Nasdaq Stockholm Small Cap (OMX: SANION). Read more at\u202f<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=kJJoFyWT2uWtgn40JgjXF9D5ErSvgrI2jsQJ-jkCbITDJ2-T7nanb4nhtS5YZ7bJfW163nQLibENI5BepW8rdXSzL73b8DvgohL0KV3vuRqHHEN4cONNX-9gQ44FksKYm3QLxYQFM90rLot4OpD8_fxOeOQj_bOAThskXlRGytlv6VnDCQz_HjZXS6OnvDY_iWcWAPoklBX6xphCjjXWII-ZZQVZPDg1z2vadlz8X1s=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.saniona.com<\/a>.\u00a0<\/p>\n<p id=\"gnw_attachments_section-header\">\n        <strong>Attachment<\/strong>\n      <\/p>\n<ul id=\"gnw_attachments_section-items\">\n<li>\n          <a target=\"_blank\" href=\"https:\/\/ml-eu.globenewswire.com\/Resource\/Download\/888c92f9-665f-4f3a-b2e9-6c525396f6c7\" rel=\"noopener noreferrer\">20210316 &#8211; Saniona Q4 Report UK vFINAL<\/a>\n        <\/li>\n<\/ul>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ2MjgzNCM0MDA4ODYwMDYjMjA0OTkwNQ==\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml-eu.globenewswire.com\/release\/track\/dd8c984b-a8e5-4a67-931c-20c3f6d8585f\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>PRESS RELEASE Financial highlights Jan &#8211; Dec 2020 (Jan &#8211; Dec 2019 restated) Revenue was SEK 8.2 M (7.2 M)Operating loss was SEK -159.4 (-93.6 M)Net loss was SEK -73.4 M (-68.8 M)Earnings per share were SEK -1.79 (-2.67)Diluted earnings per share were SEK -1.75 (-2.67) Q4 2020 (Q4 2019 restated) Revenue was SEK 1.6 M (0.0 M)Operating loss was SEK -68.8 M (-28.2 M)Net loss was SEK -45.6 M (-6.8 M)Earnings per share were SEK -0.73 (-0.24)Diluted earnings per share were SEK -0.73 (-0.24) Business highlights in Q4 2020 Saniona achieved positive top-line Phase 2 results from the open-label extension study of Tesomet in patients with HO. Patients treated with Tesomet for nearly one year (24 weeks in a &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/saniona-publishes-its-year-end-report-for-2020\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Saniona publishes its year-end report for 2020&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-459335","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Saniona publishes its year-end report for 2020 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/saniona-publishes-its-year-end-report-for-2020\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Saniona publishes its year-end report for 2020 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PRESS RELEASE Financial highlights Jan &#8211; Dec 2020 (Jan &#8211; Dec 2019 restated) Revenue was SEK 8.2 M (7.2 M)Operating loss was SEK -159.4 (-93.6 M)Net loss was SEK -73.4 M (-68.8 M)Earnings per share were SEK -1.79 (-2.67)Diluted earnings per share were SEK -1.75 (-2.67) Q4 2020 (Q4 2019 restated) Revenue was SEK 1.6 M (0.0 M)Operating loss was SEK -68.8 M (-28.2 M)Net loss was SEK -45.6 M (-6.8 M)Earnings per share were SEK -0.73 (-0.24)Diluted earnings per share were SEK -0.73 (-0.24) Business highlights in Q4 2020 Saniona achieved positive top-line Phase 2 results from the open-label extension study of Tesomet in patients with HO. Patients treated with Tesomet for nearly one year (24 weeks in a &hellip; Continue reading &quot;Saniona publishes its year-end report for 2020&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/saniona-publishes-its-year-end-report-for-2020\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-17T07:03:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ2MjgzNCM0MDA4ODYwMDYjMjA0OTkwNQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/saniona-publishes-its-year-end-report-for-2020\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/saniona-publishes-its-year-end-report-for-2020\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Saniona publishes its year-end report for 2020\",\"datePublished\":\"2021-03-17T07:03:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/saniona-publishes-its-year-end-report-for-2020\\\/\"},\"wordCount\":947,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/saniona-publishes-its-year-end-report-for-2020\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDQ2MjgzNCM0MDA4ODYwMDYjMjA0OTkwNQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/saniona-publishes-its-year-end-report-for-2020\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/saniona-publishes-its-year-end-report-for-2020\\\/\",\"name\":\"Saniona publishes its year-end report for 2020 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/saniona-publishes-its-year-end-report-for-2020\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/saniona-publishes-its-year-end-report-for-2020\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDQ2MjgzNCM0MDA4ODYwMDYjMjA0OTkwNQ==\",\"datePublished\":\"2021-03-17T07:03:25+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/saniona-publishes-its-year-end-report-for-2020\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/saniona-publishes-its-year-end-report-for-2020\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/saniona-publishes-its-year-end-report-for-2020\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDQ2MjgzNCM0MDA4ODYwMDYjMjA0OTkwNQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDQ2MjgzNCM0MDA4ODYwMDYjMjA0OTkwNQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/saniona-publishes-its-year-end-report-for-2020\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Saniona publishes its year-end report for 2020\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Saniona publishes its year-end report for 2020 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/saniona-publishes-its-year-end-report-for-2020\/","og_locale":"en_US","og_type":"article","og_title":"Saniona publishes its year-end report for 2020 - Market Newsdesk","og_description":"PRESS RELEASE Financial highlights Jan &#8211; Dec 2020 (Jan &#8211; Dec 2019 restated) Revenue was SEK 8.2 M (7.2 M)Operating loss was SEK -159.4 (-93.6 M)Net loss was SEK -73.4 M (-68.8 M)Earnings per share were SEK -1.79 (-2.67)Diluted earnings per share were SEK -1.75 (-2.67) Q4 2020 (Q4 2019 restated) Revenue was SEK 1.6 M (0.0 M)Operating loss was SEK -68.8 M (-28.2 M)Net loss was SEK -45.6 M (-6.8 M)Earnings per share were SEK -0.73 (-0.24)Diluted earnings per share were SEK -0.73 (-0.24) Business highlights in Q4 2020 Saniona achieved positive top-line Phase 2 results from the open-label extension study of Tesomet in patients with HO. Patients treated with Tesomet for nearly one year (24 weeks in a &hellip; Continue reading \"Saniona publishes its year-end report for 2020\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/saniona-publishes-its-year-end-report-for-2020\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-17T07:03:25+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ2MjgzNCM0MDA4ODYwMDYjMjA0OTkwNQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/saniona-publishes-its-year-end-report-for-2020\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/saniona-publishes-its-year-end-report-for-2020\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Saniona publishes its year-end report for 2020","datePublished":"2021-03-17T07:03:25+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/saniona-publishes-its-year-end-report-for-2020\/"},"wordCount":947,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/saniona-publishes-its-year-end-report-for-2020\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ2MjgzNCM0MDA4ODYwMDYjMjA0OTkwNQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/saniona-publishes-its-year-end-report-for-2020\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/saniona-publishes-its-year-end-report-for-2020\/","name":"Saniona publishes its year-end report for 2020 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/saniona-publishes-its-year-end-report-for-2020\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/saniona-publishes-its-year-end-report-for-2020\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ2MjgzNCM0MDA4ODYwMDYjMjA0OTkwNQ==","datePublished":"2021-03-17T07:03:25+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/saniona-publishes-its-year-end-report-for-2020\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/saniona-publishes-its-year-end-report-for-2020\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/saniona-publishes-its-year-end-report-for-2020\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ2MjgzNCM0MDA4ODYwMDYjMjA0OTkwNQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ2MjgzNCM0MDA4ODYwMDYjMjA0OTkwNQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/saniona-publishes-its-year-end-report-for-2020\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Saniona publishes its year-end report for 2020"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/459335","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=459335"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/459335\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=459335"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=459335"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=459335"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}